Overall, these data showed that HCQ has a specific effect in inhibiting the ability of anti-PD-1 immunotherapy to increase the generation of CD8+ PD-1+ TCF1+ and CD8+ CD44+ PD-1+ TCF1+ progenitor TILs relative to tumor volume. This evidence concerns the gene CD44 and neoplasm.